Bausch Health Unveils Fraxel FTX™ Laser System, Elevating the Standard in Skin Resurfacing

Key Highlights:

• Bausch Health launches next-gen Fraxel FTX™ at ASLMS 2025 in Orlando
• New design enhances precision, comfort, and efficiency for aesthetic treatments
• Dual-wavelength laser offers visible results with minimal downtime
• Global rollout planned after U.S. debut

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its aesthetic arm, Solta Medical, are making waves in the global aesthetics market with the launch of Fraxel FTX™, the next evolution of their industry-renowned laser skin resurfacing technology. Announced today at the American Society for Laser Medicine & Surgery (ASLMS) 2025 Annual Conference in Orlando, this upgraded platform is expected to redefine how aesthetic professionals approach skin rejuvenation treatments.

The Fraxel brand has long been a cornerstone in aesthetic medicine, known for its effectiveness in treating wrinkles, acne scars, pigmentation, and sun damage. With Fraxel FTX™, Bausch Health is reinforcing its leadership position by blending advanced laser capabilities with ergonomic innovation, all while keeping patient comfort front and center.

“This is more than just an upgrade — it’s a leap forward,” said Thomas J. Appio, CEO of Bausch Health. “Fraxel FTX™ reflects our vision to deliver powerful tools that enhance both clinical outcomes and patient experience. The launch marks a pivotal moment in our commitment to advancing aesthetic care.”

Next-Gen Features That Make a Difference

What sets Fraxel FTX™ apart is its dual-wavelength fractional laser system, leveraging 1550 nm erbium-glass and 1927 nm thulium lasers to target multiple layers of skin. This combination allows for precise treatment of deep and superficial skin concerns while promoting rapid healing — a key demand from today’s on-the-go patient demographic.

Ergonomic improvements such as a 20% lighter handpiece, integrated cooling technology, and a newly designed console enhance usability for clinicians. A reimagined Intelligent Optical Tracking® with AccuTRAC™ system ensures more consistent and efficient treatment delivery.

According to Jiny Kim, SVP at Solta Medical, “Fraxel FTX™ keeps the trusted fundamentals while offering more intuitive controls, smarter design, and superior outcomes across a broader range of skin types.”

Stock Snapshot

As of late morning trading on April 25, Bausch Health shares were down 2.01%, at $5.37, after opening at $5.47. The stock has moved between $5.32 and $5.47 during the session so far. With a 52-week range of $3.96 to $9.85, BHC has seen mixed sentiment this year. The company carries a market cap of $1.98 billion, and its average daily volume stands at roughly 2.6 million shares. Earnings are scheduled for release on April 30, 2025, a potential catalyst as investors evaluate the company’s new product rollout.

Market Timing and Global Expansion

The timing couldn’t be more strategic. As demand for non-invasive aesthetic solutions rises globally, Bausch Health aims to capitalize with an expanded rollout of Fraxel FTX™ beyond the U.S. later this year.

Meanwhile, with BHC stock trading actively on both the NYSE and TSX, investors are closely watching how innovation within Solta Medical contributes to Bausch’s broader growth strategy. The company’s push into high-margin aesthetics aligns with its long-term vision of becoming a globally integrated healthcare leader.

As Bausch continues to expand its influence in the aesthetics market, Fraxel FTX™ could be the next key growth engine for both the company — and its investors.